Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada

Mankind Pharma collaborates with OpenAI to drive AI-enabled transformation across value chain

The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

Biocon Biologics receives FDA approval for Bosaya and Aukelso biosimilars

Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India

Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB

Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093

MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile

Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas

The cGMP-4 facility will further strengthen the company's ability to serve global partners

SPL Infusion commences commercial production of new IV fluid Infusion plant

The facility has been designed with a dual focus on efficiency and sustainability

FDA grants Fast Track Designation for Teva’s Emrusolmin

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development

Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC

The company has received approval from DCGI to begin patient enrolment and dosing in the country